|
|
 |
|
Viewing report
|
|
|
|
Colorectal Cancer Drug Futures 2010
Espicom Business Intelligence Ltd, Oct 2010, Pages: 284
Early-stage colorectal cancer (CRC) is generally treated with surgery and radiation with a high percentage of patients going on to survive disease free. Unfortunately, only around 40% of CRCs are found at this early stage, and, as a result, there remains considerable unmet clinical need within the CRC market.
For those patients who experience recurrence following surgery there is a clear need for effective therapies earlier in the course of the disease. In addition, with around 76% of patients (Stages II-IV) eligible for chemotherapy, new formulations which improve patients' quality of life and increase survival are sorely needed.
In 2008, the CRC drug market (US, EU and Japan) for major branded therapies were valued at just over US$8 billion. Whilst chemotherapy is the mainstay of CRC treatment the use of targeted therapies are gaining acceptances in the treatment of advanced disease. This trend is expected to continue as new combinations are evaluated and therapies are increasingly used in the adjuvant setting to address the unmet clinical needs within the market. Indeed, by 2015 targeted therapies will account for 77% of the CRC market.
Which products and companies will benefit from this trend?
NOW YOU CAN STAY IN TOUCH WITH THE DEVELOPMENTS WHICH MATTER
This all new web service, Colorectal Cancer Drug Futures, assesses the future prospects for market success for individual drugs. Based on independent research and proprietary analysis, each product assessed brings the prospects for a product into clear focus. Best of all, each drug is regularly reviewed ensuring that latest developments are incorporated for you to see.
WITH EACH KEY DRUG ANALYSED IN THIS SERVICE YOU CAN:
- Track the drug’s progress and stay abreast of developments
- Understand the drug’s novelty and mode of action
- Evaluate the strength of the company developing/producing the drug
- Review opportunities and challenges with the analsysts unique 5-point competitive assessment
- Know the launch timeframe for new products or indications
- Be aware of promising mid-stage development candidates
- Estimate future revenues with original 5-year forecasts for launched and leading pipeline candidates
- Review significant clinical trial results
STRUCTURED ANALYSIS OF KEY DRIVERS AND DAMPENERS OF SUCCESS
For each product analysed there is an extensive and standardised review of the factors which can affect its clinical and commercial performance. Those factors include…
- Novelty/rationale for mechanism of action
- Current status
- Proof of concept/clinical data
- Development risks
- Company expertise
- Competition within the market-place
- Sales forecast (for key late-stage and launched products)
- Competitor ratio analysis score
- Clinical trial results
50 CRC ACTIVE DRUGS INCLUDE:
Because this service is continually updated, products will be added, deleted or enhanced in response to ongoing developments throughout the course of your licence. From time-to-time drug profiles may be removed from the service for essential updating.
- Approved
- Bevacizumab
- Capecitabine
- Cetuximab
- Doxifluridine
- Irinotecan
- Oxaliplatin
- Panitumumab
- Phase III
- Aflibercept
- Brivanib
- Cediranib
- HA-irinotecan
- OncoVAX
- Perifosine
- Regorafenib
- Talaporfin sodium
- Phase II/III
- Canfosfamide
- Phase II
- Adecatumumab
- Angiocept
- Arenegyr
- AZD6244
- BIBF 1120
- Cixutumumab
- Conatumumab
- CPX-1
- CS-7017
- Davanat
- Enzastaurin
- Figitumumab
- GDC-0449
- Gimatecan
- Linifanib
- Mapatumumab
- Necitumumab
- Pemetrexed disodium
- Picoplatin
- Ramucirumab
- RG 7204
- SAR109659
- Sorafenib
- Sunitinib
- TAS-102
- Telatinib
- Tigatuzumab
- Phase I/II
- ARQ 197
- EMD525797
- Phase I
- 184072
- Dulanermin
- IMO-2055
- Interleukin-21
- Pazopanib
- Tivozanib
- Discontinued
- ABT-751
- GDC-0449
- PD-325901
- Trastuzumab
CLEAR, CONCISE, AND ORIGINAL ANALYSIS GIVES YOU KEY PRODUCT INSIGHTS
The Cancer Drug Futures incorporate the latest analysis from our in-house team of life scientists and statisticians across a range of cancer areas. Their research builds upon the analysts established knowledge base of up-to-date intelligence on thousands of pharmaceutical manufacturers and research companies, backed up by a fifteen years’ of archive material.
Taking all aspects of the market into account, from clinical trials, deals and alliances to company financial performance and drug sales, the analysis and forecasting that contributes to the Cancer Drug Futures is standardised across each individual launched product or drug candidate and is founded upon a diligent and thorough research process.
With the Cancer Drug Futures you can easily evaluate the prospects of the drugs of interest to you and discover its progress in each indication. Each report provides individual and highly-detailed analysis of the drug, looking at the key factors affecting its future performance in the marketplace.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Breast Cancer Drug Futures 2010
Lung Cancer Drug Futures 2010
Renal Cell Carcinoma Cancer Drug Futures 2010
Prostate Cancer Drug Futures 2010
Will Anyone Crack the Obesity Drug Market?
Multiple Sclerosis Drug Discoveries - What the Future Holds
Ophthalmology Drug Futures: Sight Preservation in Chronic Eye Diseases
Threats to Avastin - Targeting the VEGF Pathway
Cancer Drug Blockbusters to 2016
MRSA Drug Futures
|
|
|
|
